UPDATED: May 15, 2019
Quality should be built into the entire drug product lifecycle – including the manufacturing and production process – to help protect patient safety and build trust in medicines. The same is true for compounded medicines.
The quality of medicine and how it’s delivered to patients is fundamental to treating illness and maintaining health. At USP, we help build a safety net across the drug industry and healthcare system to preserve the well-being of patients.
In conversations about the role of quality standards in public health, you might come across the words “compendia” and “compendial.” At USP, terms like “compendial approaches,” “compendial standards,” and “compendial tools” are part of our everyday vocabulary.
Gigi Davidson, R.Ph., DICVP, Chair of USP's Compounding Expert Committee shares her thoughts and background information on proposed revisions to <797> Pharmaceutical Compounding—Sterile Preparations. Compounding practitioners are encouraged to view and share comments on the changes online.
Tiffany Chan, a PharmD candidate from Shenandoah University, details her rewarding experience participating in the 2015 USP Summer Internship Program.
Compounding plays a critical role in treating and preventing disease when commercially available medicine is unsuitable. USP has developed standards for compounding practitioners since 1820, and presently provides three types of standards to help ensure quality compounded medicines.
Chemotherapy medicines and drugs that can be considered hazardous, are lifesaving for patients, but repeat exposure poses significant health risks for the nurses and pharmacists who prepare and administer them. This week, USP announced it will publish revisions to a proposed chapter on the handling of hazardous drugs in healthcare settings. It is just the latest example of the inclusive, informed, and transparent debate provided by USP on topics of critical importance to pharmacy and healthcare practice